Results 51 to 60 of about 3,067,072 (318)

Waiting for JAK inhibitor safety data [PDF]

RMD Open, 2022
The US Food and Drug Administration (FDA) has recently added a new ‘black box warning’ on all currently approved Janus kinase (JAK) inhibitors indicated for the treatment of arthritis and other inflammatory conditions based on results from the ORAL Surveillance study of tofacitinib versus tumour necrosis factor alpha inhibitors in rheumatoid arthritis.
Tue Wenzel Kragstrup, Bente Glintborg, Annemarie L Svensson, Christopher McMaster, Philip C Robinson, Bent Deleuran, David FL Liew   +6 more
openaire   +7 more sources

Targeting the Janus Kinase Family in Autoimmune Skin Diseases

Frontiers in Immunology, 2019
Autoimmune skin diseases are characterized by significant local and systemic inflammation that is largely mediated by the Janus kinase (JAK)–signal transducer and activator of transcription (STAT) pathway.
Michael D. Howell, Fiona I. Kuo, Paul A. Smith   +2 more
doaj   +1 more source

Risk of venous thromboembolism with janus kinase inhibitors in inflammatory immune diseases: a systematic review and meta-analysis

Frontiers in Pharmacology, 2023
Objectives: This study aimed to evaluate the risk of venous thrombosis (VTE) associated with Janus kinase (JAK) inhibitors in patients diagnosed with immune-mediated inflammatory diseases.Methods: We conducted a comprehensive search of PUBMED, Cochrane ...
Juqi Zhang, Juqi Zhang, Juqi Zhang, Wenhui Li, Wenhui Li, Wenhui Li, Mingli Gong, Yanlun Gu, Yanlun Gu, Yanlun Gu, Hanxu Zhang, Hanxu Zhang, Hanxu Zhang, Bingqi Dong, Qi Guo, Qi Guo, Qi Guo, Xiaocong Pang, Xiaocong Pang, Qian Xiang, Qian Xiang, Xu He, Xu He, Yimin Cui, Yimin Cui, Yimin Cui   +25 more
doaj   +1 more source

Managing Cardiovascular and Cancer Risk Associated with JAK Inhibitors

Drug Safety, 2023
Janus kinase inhibitors (JAKi) have enormous appeal as immune-modulating therapies across many chronic inflammatory diseases, but recently this promise has been overshadowed by questions regarding associated cardiovascular and cancer risk emerging from ...
V. Yang, T. Kragstrup, C. McMaster, P. Reid, Namrata Singh, S. Haysen, P. Robinson, D. Liew   +7 more
semanticscholar   +1 more source

Therapeutic role of JAK inhibitors in hepatogastrointestinal diseases [PDF]

Exploration of Digestive Diseases
Janus kinase (JAK) inhibitors represent a major advancement in the management of immune-mediated inflammatory diseases. A balanced approach that carefully weighs therapeutic benefits against potential risks is essential.
Maged Tharwat Elghannam, Moataz Hassan Hassanien, Yosry Abdelrahman Ameen, Emad Abdelwahab Turky, Gamal Mohammed Elattar, Ahmed Aly Elray, Mohammed Darwish Eltalkawy   +6 more
doaj   +1 more source

Effect of JAK inhibitors on the three forms of bone damage in autoimmune arthritis: joint erosion, periarticular osteopenia, and systemic bone loss

Inflammation and Regeneration, 2023
Background The types of bone damage in rheumatoid arthritis (RA) include joint erosion, periarticular osteoporosis, and systemic osteoporosis. Janus kinase (JAK) inhibitors ameliorate inflammation and joint erosion in RA, but their effect on the three ...
Masatsugu Komagamine, Noriko Komatsu, Rui Ling, Kazuo Okamoto, Shi Tianshu, Kotaro Matsuda, Tsutomu Takeuchi, Yuko Kaneko, Hiroshi Takayanagi   +8 more
doaj   +1 more source

Recent advances in JAK inhibitors for the treatment of metabolic syndrome

Frontiers in Pharmacology, 2023
With an epidemic spread, metabolic syndrome represents an increasingly emerging risk for the population globally, and is currently recognized as a pathological entity.
D. Collotta, Mariausilia Franchina, Virginia Carlucci, M. Collino   +3 more
semanticscholar   +1 more source

JAK3 as an Emerging Target for Topical Treatment of Inflammatory Skin Diseases. [PDF]

PLoS ONE, 2016
The recent interest and elucidation of the JAK/STAT signaling pathway created new targets for the treatment of inflammatory skin diseases (ISDs). JAK inhibitors in oral and topical formulations have shown beneficial results in psoriasis and alopecia ...
Ana Karina Alves de Medeiros, Reinhart Speeckaert, Eline Desmet, Mireille Van Gele, Sofie De Schepper, Jo Lambert   +5 more
doaj   +1 more source

Use of JAK Inhibitors in Dermatomyositis: A Systematic Literature Review

Clinical and Experimental Rheumatology, 2022
Dermatomyositis (DM) is an idiopathic inflammatory myopathy that commonly manifests with proximal muscle weakness and is associated with extramuscular pathology including characteristic skin lesions such as Gottron’s papules and heliotrope rash, as well ...
Julie J. Paik, G. Lubin, Austin A. Gromatzky, P. Mudd, M. Ponda, L. Christopher‐Stine   +5 more
semanticscholar   +1 more source

JAK Inhibitors as Potential Therapeutic Strategy for the Dilemma of Psoriasis Concurrent with Dermatomyositis in the SARS-CoV-2 Era

, 2023
Qiannan Xu, Nan Xu Department of Dermatology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, People’s Republic of ChinaCorrespondence: Nan Xu, Tel +86 38804518, Email xnhrb@sina.comAbstract: Dermatomyositis is a rare inflammatory
Xu N, Xu Q
core